Hem › Major depression › Florida › Tampa
Kliniska studier för Major depression i Tampa, FL
17 studier för Major depression söker deltagare vid platser i och runt Tampa (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
RekryterarFas 2
- IPTB Clinical Research, Tampa
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
RekryterarFas 3
- K2 Medical Research Tampa, Tampa
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
RekryterarFas 3
- K2 Medical Research (Tampa), Tampa
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
RekryterarFas 3
- K2 Medical Research - Tampa, Tampa
A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
RekryterarFas 3
- IPTB Clinical Research, Tampa
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
RekryterarFas 3
- Interventional Psychiatry of Tampa Bay, Tampa
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
RekryterarFas 3
- Psych Me Medical Research Inc, Tampa
- Interventional Psychiatry of Tampa Bay, Tampa
A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
RekryterarFas 2
- K2 Medical Research - Tampa, Tampa
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RekryterarFas 4
- Neurocrine Clinical Site, Tampa
A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
RekryterarFas 2
- Draig Clinical Site, Tampa
- Draig Clinical Site, Tampa
Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
Rekryterar
- USF Health, Tampa
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RekryterarFas 3
- Neurocrine Clinical Site, Tampa
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RekryterarFas 3
- Neurocrine Clinical Site, Tampa
- Neurocrine Clinical Site, Tampa
A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RekryterarFas 3
- Neurocrine Clinical Site, Tampa
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
RekryterarFas 2
- University of South Florida, Psychiatry and Behavioral Neurosciences, Tampa
Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
RekryterarFas 2
- Autobahn Site #148, Tampa
Study of ALTO-300 in MDD
RekryterarFas 2
- Site 221, Tampa
Major depression-studier i andra städer
- New York City, NY36 studier
- Boston, MA31 studier
- Atlanta, GA25 studier
- Philadelphia, PA23 studier
- Orlando, FL19 studier
- Miami, FL18 studier
- Chicago, IL17 studier
- San Diego, CA16 studier
- Houston, TX16 studier
- Little Rock, AR14 studier
- Austin, TX13 studier
- Las Vegas, NV13 studier
Andra studier i Tampa
- Icke-småcellig lungcancer51 studier
- Bröstcancer43 studier
- Cancer (alla typer)39 studier
- Kolorektal cancer34 studier
- Akut myeloid leukemi29 studier
- Metastaserande cancer29 studier
- Lungcancer29 studier
- Bukspottkörtelcancer26 studier
- Äggstockscancer21 studier
- Melanom19 studier
- Myelodysplastiska syndrom19 studier
- Prostatacancer18 studier
Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.